Egyptian HCV Patient Records with 18-Month Treatment and Liver Fibrosis Prediction

A 2017 dataset of Egyptian patients who underwent Hepatitis C Virus (HCV) treatment dosages for about 18 months. The data includes demographic, symptom, blood test, and RNA level measurements, collected for a model predicting liver fibrosis via non-invasive methods. It was published by Mahmoud Nasr et al. at the International Computer Engineering Conference.

Use Cases

• Predicting liver fibrosis progression based on non-invasive clinical and blood test features.
• Analyzing the relationship between alanine transaminase (ALT) ratios over time and treatment outcomes.
• Modeling patient response to HCV treatment based on RNA levels and baseline histological grading.

Strengths

• Includes longitudinal data for key biomarkers like ALT and RNA over an 18-month treatment period.
• Contains a mix of demographic, symptomatic, and detailed laboratory test features for model building.

Limitations

• Row count and dataset size are unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.

Provenance

Source

UCI and Nasr, M., El-Bahnasy, K., Hamdy, M., & Kamal, S. M.

Collection Method

Clinical records from Egyptian patients undergoing HCV treatment.

Time Range

Treatment period of about 18 months; dataset published in 2017.

Freshness

Last update date is unknown; freshness unverified.

Geography

Egypt